CAJ | 학술논문

目的：探讨抗CD20单抗联合化疗治疗侵袭性B细胞非霍奇金淋巴瘤（ B-NHL）的临床疗效。方法将40例侵袭性B-NHL患者随机分为观察组和对照组，每组20例，对照组采用CHOP方案化疗，观察组在对照组的基础上加用抗CD20单克隆抗体利妥昔治疗，比较两组的疗效及不良反应。结果观察组治疗后完全缓解13例，部分缓解3例，总有效率为80．0％（16／20），显著高于对照组40．0％（8／20），P＜0．05。不良反应发热例数观察组显著多于对照组，P＜0．05。其他不良反应两组无显著性差异，P＞0．05。结论抗CD20单抗联合化疗治疗侵袭性B-NHL有较好的近期疗效，不良反应可耐受，有利于改善患者的生存质量。
목적：탐토항CD20단항연합화료치료침습성B세포비곽기금림파류（ B-NHL）적림상료효。방법장40례침습성B-NHL환자수궤분위관찰조화대조조，매조20례，대조조채용CHOP방안화료，관찰조재대조조적기출상가용항CD20단극륭항체리타석치료，비교량조적료효급불량반응。결과관찰조치료후완전완해13례，부분완해3례，총유효솔위80．0％（16／20），현저고우대조조40．0％（8／20），P＜0．05。불량반응발열례수관찰조현저다우대조조，P＜0．05。기타불량반응량조무현저성차이，P＞0．05。결론항CD20단항연합화료치료침습성B-NHL유교호적근기료효，불량반응가내수，유리우개선환자적생존질량。
Objective To study the clinical efficacy of anti-CD20 monoclonal antibody combined with chemotherapy for aggressive B cell non-Hodgkin's lymphoma ( B-NHL) .Methods 40 cases of aggressive B-NHL were randomly divided into the observation group(n=20) and the control group(n=20).The control group were treated with CHOP chemotherapy,and the ob-servation group received anti-CD20 monoclonal antibody rituximab on the basis of the control group,the efficacy and toxicity of the 2 groups were compared.Results After treatment in the observation group,complete remission was 13 cases,partial remission was 3 cases,the total effective rate was 80.0% (16/20),which was significantly higher than that of the control group 40.0%(8/20),P<0.05.Fever cases in the observation group were significantly less than those of the control group,P<0.05.Other ad-verse reactions of the 2 groups had no significant difference,P>0.05.Conclusion Anti-CD20 monoclonal antibody combined with chemotherapy for aggressive B-NHL has good short-term effects with tolerable adverse reactions,it helps to improve the quali-ty of life of patients.